ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BIOC Biocept Inc

0.4349
0.00 (0.00%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Biocept Inc NASDAQ:BIOC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.4349 0.37 0.3799 0 01:00:00

Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023

14/06/2023 9:05pm

Business Wire


Biocept (NASDAQ:BIOC)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Biocept Charts.

Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday, June 20 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). Biocept’s discussion will be hosted by Maxim Group Senior Research Analyst Michael Okunewitch.

Registration information to become an M-Vest member for access to the live and archived presentation webcast is posted to Events & Presentations section of the Biocept website.

About M-Vest

M-Vest is a division of Maxim Group LLC that serves to allows investors access to investment opportunities online and to provide a digital community built for issuers, investors, and thought leaders to share information. The platform provides insights on current market trends through presentations from innovative emerging growth companies and commentary from industry thought leaders via live events and Q&A.

About Biocept

Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Our experts have spent years working to change the way physicians look at cerebrospinal fluid in cancer patients. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, Biocept is a leading commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample.

Investor and Media Contact: Jody Cain, LHA Investor Relations Jcain@lhai.com, 310-691-7100

1 Year Biocept Chart

1 Year Biocept Chart

1 Month Biocept Chart

1 Month Biocept Chart

Your Recent History

Delayed Upgrade Clock